D.A. Davidson & Co’s Novo Nordisk NVO Stock Holding History

D.A. Davidson & Co’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.72M	Buy	56,812 +1,576	+3%	+$67.7K	0.02%	637
2026 Q1	$2.03M	Buy	55,236 +9,605	+21%	+$455K	0.01%	693
2025 Q4	$2.32M	Buy	45,631 +5,397	+13%	+$276K	0.01%	623
2025 Q3	$2.23M	Sell	40,234 -184	-0.5%	-$10.8K	0.01%	613
2025 Q2	$2.79M	Buy	40,418 +14,091	+54%	+$958K	0.02%	502
2025 Q1	$1.83M	Sell	26,327 -6,052	-19%	-$500K	0.01%	592
2024 Q4	$2.79M	Sell	32,379 -18,833	-37%	-$2.04M	0.02%	466
2024 Q3	$6.1M	Buy	51,212 +12,399	+32%	+$1.65M	0.05%	275
2024 Q2	$5.54M	Buy	38,813 +7,884	+25%	+$1.04M	0.05%	279
2024 Q1	$3.97M	Buy	30,929 +4,364	+16%	+$519K	0.04%	351
2023 Q4	$2.75M	Buy	26,565 +3,129	+13%	+$309K	0.03%	414
2023 Q3	$2.13M	Buy	23,436 +2,724	+13%	+$240K	0.02%	465
2023 Q2	$1.68M	Buy	20,712 +2,914	+16%	+$238K	0.02%	530
2023 Q1	$1.41M	Sell	17,798 -586	-3%	-$41.6K	0.02%	555
2022 Q4	$1.24M	Buy	18,384 +876	+5%	+$51.4K	0.01%	567
2022 Q3	$874K	Sell	17,508 -316	-2%	-$16.9K	0.01%	623
2022 Q2	$993K	Buy	17,824 +414	+2%	+$23K	0.01%	602
2022 Q1	$967K	Buy	17,410 +1,180	+7%	+$60.6K	0.01%	665
2021 Q4	$908K	Buy	16,230 +4,438	+38%	+$240K	0.01%	684
2021 Q3	$566K	Buy	11,792 +1,200	+11%	+$58K	0.01%	798
2021 Q2	$444K	Buy	10,592 +210	+2%	+$8.14K	0.01%	868
2021 Q1	$350K	Buy	10,382 +100	+1%	+$3.56K	﹤0.01%	910
2020 Q4	$359K	Sell	10,282 -1,500	-13%	-$51.8K	0.01%	802
2020 Q3	$409K	Buy	11,782 +2,600	+28%	+$86.7K	0.01%	674
2020 Q2	$301K	Sell	9,182 -1,158	-11%	-$37K	0.01%	749
2020 Q1	$311K	Sell	10,340 -256	-2%	-$7.62K	0.01%	730
2019 Q4	$307K	Buy	10,596 +788	+8%	+$21.8K	0.01%	810
2019 Q3	$254K	Sell	9,808 -2,470	-20%	-$62.5K	﹤0.01%	839
2019 Q2	$313K	Sell	12,278 -10,984	-47%	-$271K	0.01%	772
2019 Q1	$608K	Sell	23,262 -110,600	-83%	-$2.72M	0.01%	636
2018 Q4	$3.08M	Sell	133,862 -6,092	-4%	-$135K	0.06%	255
2018 Q3	$3.3M	Buy	139,954 +122	+0.1%	+$2.98K	0.06%	256
2018 Q2	$3.23M	Sell	139,832 -3,280	-2%	-$78K	0.06%	252
2018 Q1	$3.52M	Buy	143,112 +5,152	+4%	+$135K	0.07%	223
2017 Q4	$3.7M	Sell	137,960 -3,640	-3%	-$92.6K	0.08%	205
2017 Q3	$3.41M	Buy	141,600 +2,228	+2%	+$50.3K	0.07%	254
2017 Q2	$2.99M	Sell	139,372 -1,076	-0.8%	-$21.7K	0.07%	227
2017 Q1	$2.41M	Sell	140,448 -95,028	-40%	-$1.65M	0.06%	267
2016 Q4	$4.22M	Buy	235,476 +12,114	+5%	+$220K	0.1%	205
2016 Q3	$4.64M	Buy	223,362 +4,614	+2%	+$114K	0.12%	183
2016 Q2	$5.88M	Sell	218,748 -1,550	-0.7%	-$42.5K	0.17%	118
2016 Q1	$5.96M	Sell	220,298 -13,698	-6%	-$367K	0.19%	108
2015 Q4	$6.79M	Sell	233,996 -7,546	-3%	-$209K	0.22%	94
2015 Q3	$6.55M	Buy	241,542 +1,248	+0.5%	+$35.3K	0.23%	89
2015 Q2	$6.58M	Buy	240,294 +3,308	+1%	+$93K	0.22%	98
2015 Q1	$6.32M	Sell	236,986 -72,900	-24%	-$1.68M	0.21%	102
2014 Q4	$6.55M	Buy	309,886 +6,062	+2%	+$135K	0.21%	97
2014 Q3	$7.23M	Sell	303,824 -5,902	-2%	-$136K	0.25%	82
2014 Q2	$7.15M	Sell	309,726 -26,516	-8%	-$585K	0.24%	82
2014 Q1	$7.67M	Buy	336,242 +412	+0.1%	+$8.78K	0.27%	76
2013 Q4	$6.2M	Buy	335,830 +13,430	+4%	+$234K	0.23%	85
2013 Q3	$5.45M	Buy	322,400 +23,900	+8%	+$402K	0.25%	86
2013 Q2	$4.62M	Buy	+298,500	New	+$4.97M	0.22%	97

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

D.A. Davidson & Co's NVO Position: Q2 2026 in Review

D.A. Davidson & Co increased its Novo Nordisk (NVO) stake by 2.9% in Q2 2026, buying an estimated $67.7K and bringing the position to 56,812 shares worth $2.72M. The position accounts for 0.02% of the portfolio, ranked #637.

D.A. Davidson & Co first reported a position in NVO in Q2 2013 and has held it in 53 quarters since. The position peaked at $7.67M in Q1 2014. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

D.A. Davidson & Co held 56,812 shares of Novo Nordisk worth $2.72M as of Q2 2026.
D.A. Davidson & Co bought 1,576 Novo Nordisk shares in Q2 2026, an estimated $67.7K.
Novo Nordisk made up 0.02% of D.A. Davidson & Co's portfolio in Q2 2026, its #637 holding.
D.A. Davidson & Co first reported a position in Novo Nordisk in Q2 2013 and has held it in 53 quarters since.
D.A. Davidson & Co's Novo Nordisk position peaked at $7.67M in Q1 2014.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on D.A. Davidson & Co's 13F filing for Q2 2026, filed 24 Jul 2026.